MMP/ADAM inhibitors: therapeutic potential for psoriasis

Bibliography

• GREAVES MW, WEINSTEIN GD: Treatment of psoriasis. N Engl. J. Med. (1995) 332:581–588.
   PubMed Web of Science ®Google Scholar
• NICKOLOFF BJ, NESTLE FO: Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. (2004) 113:1664–1675.
   PubMed Web of Science ®Google Scholar
• •Recent insights into pathogenesis of psoriasis are discussed.
   Google Scholar
• KUPPER TS: Immunologic targets in psoriasis. N Engl. J. Med. (2003) 349:1987–1990.
   PubMed Web of Science ®Google Scholar
• HASHIMOTO K: Regulation of keratinocyte function by growth factors. J. Dermatol Sci. (2000) 24\(Supp1.1):546–50.
   Google Scholar
• WRAIGHT CJ, WHITE PJ, MCKEAN SC et al.: Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides. Nat. Biotechnol. (2000) 18:521–526.
   PubMed Web of Science ®Google Scholar
• DI MARCO E, MATHOR M, BONDANZA S et al.: Nerve growth factor binds to normal human keratinocytes through high and low affinity receptors and stimulates their growth by a novel autocrine loop. J. Biol. Chem. (1993) 268:22838–22846.
   PubMed Web of Science ®Google Scholar
• GUO L, YU QC, FUCHS E: Targeting expression of keratinocyte growth factor to keratinocytes elicits striking changes in epithelial differentiation in transgenic mice. EMBO J. (1993) 12:973–986.
   PubMed Web of Science ®Google Scholar
• LI AG, WANG D, FENG XH, WANG XJ: Latent TGF01 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J. (2004) 23:1770–1781.
   PubMed Web of Science ®Google Scholar
• NANNEY LB, STOSCHECK CM, MAGID M, KING LE JR.: Altered ['25I]epidermal growth factor binding and receptor distribution in psoriasis. J. Invest. DermatoL (1986) 86:260–265.
   Google Scholar
• HASHIMOTO K, HIGASHIYAMA S, ASADA H et al.: Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J. Biol Chem. (1994) 269:20060–20066.
   PubMedGoogle Scholar
• COOK PW, MATTOX PA, KEEBLE WW et al.: A heparin sulfate-regulated human keratinocyte autocrine factor is similar or identical to amphiregulin. MoL Cell Biol. (1991) 11:2547–2557.
   PubMed Web of Science ®Google Scholar
• SHIRAKATA Y, KOMURASAKI T, TOYODA H et al.: Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes. J. Biol. Chem. (2000) 275:5748–5753.
   PubMed Web of Science ®Google Scholar
• COFFEY RJ JR, DERYNCK R, WILCOX JN et al.: Production and auto-induction of transforming growth factor-a in human keratinocytes. Nature (1987) 328:817–820.
   PubMedGoogle Scholar
• ZHENG Y, PENG Z, WANG Y et al: Alteration and significance of heparin-binding epidermal-growth-factor-like growth factor in psoriatic epidermis. Dermatology (2003) 207:22–27.
   PubMedGoogle Scholar
• COOK PW, PITTELKOW MR, KEEBLE WW et al.: Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. Cancer Res. (1992) 52:3224–3227.
   PubMed Web of Science ®Google Scholar
• ELDER JT, FISHER GJ, LINDQUIST PB et al: Overexpression of transforming growth factor-a in psoriatic epidermis. Science (1989) 243:811–814.
   PubMed Web of Science ®Google Scholar
• COOK PW, PITTELKOW MR, PIEPKORN M: Overexpression of amphiregulin in the epidermis of transgenic mice induces a psoriasis-like cutaneous phenotype. J. Invest. Dermatol. (1999) 113:860.
   PubMedGoogle Scholar
• COOK PW, BROWN JR, CORNELL KA, PITTELKOW MR: Suprabasal expression of human amphiregulin in the epidermis of transgenic mice induces a severe, early-onset, psoriasis-like skin pathology: expression of amphiregulin in the basal epidermis is also associated with synovitis. Exp. DermatoL (2004) 13:347–356.
   PubMed Web of Science ®Google Scholar
• •Overexpression of amphiregulin induces psoriasis-like skin phenotype in mice.
   Google Scholar
• VASSAR R, FUCHS E: Transgenic mice provide new insights into the role of TGF-a during epidermal development and differentiation. Genes Dev. (1991) 5:714–727.
   PubMed Web of Science ®Google Scholar
• NICKOLOFF BJ, KARABIN GD, BARKER JN et al: Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-a in psoriasis. Am. J. PathoL (1991) 138:129–140.
   PubMed Web of Science ®Google Scholar
• ETTEHADI P, GREAVES MW, WALLACH D et al: Elevated tumour necrosis factor-a (TNF-a) biological activity in psoriatic skin lesions. Clin. Exp. Immunol (1994) 96:146–151.
   PubMed Web of Science ®Google Scholar
• BONIFATI C, CARDUCCI M, CORDIALI FP et al: Correlated increases of tumour necrosis factor-a, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients-relationships with disease severity. Clin. Exp. DermatoL (1994) 19:383–387.
   PubMed Web of Science ®Google Scholar
• BONIFATI C, AMEGLIO F: Cytokines in psoriasis. Int. j DermatoL (1999) 38:241–251.
   PubMed Web of Science ®Google Scholar
• CHARLES P, ELLIOTT MJ, DAVIS D et al: Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-a therapy in rheumatoid arthritis. Immunol (1999) 163:1521–1528.
   Google Scholar
• LEONARDI CL, POWERS JL, MATHESON RT et al: Etanercept as monotherapy in patients with psoriasis. N Engl. J. Med. (2003) 349:2014–2022.
   PubMed Web of Science ®Google Scholar
• •Anti-TNF-a therapy led to a significant reduction in the severity of psoriasis.
   Google Scholar
• LEBWOHL M: Psoriasis. Lancet (2003) 361:1197–1204.
   PubMed Web of Science ®Google Scholar
• STONE AL, KROEGER M, SANG QX: Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase-containing proteins (review). J Protein Chem. (1999) 18:447–465.
   PubMedGoogle Scholar
• WHITTAKER M, FLOYD CD, BROWN P, GEARING AJ: Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. (1999) 99:2735–2776.
   PubMed Web of Science ®Google Scholar
• BLOBEL CP: ADAMs: key components in EGFR signalling and development. Nat. Rev. Mol Cell Biol. (2005) 6:32–43.
   PubMed Web of Science ®Google Scholar
• CHEN JM, JIN G, SUNG A, LEVIN JI: Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups. Bioorg. Med. Chem. Lett. (2002) 12:1195–1198.
   Google Scholar
• HIGASHIYAMA S, ABRAHAM JA, MILLER Jet al: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science (1991) 251:936–939.
   PubMed Web of Science ®Google Scholar
• IZUMI Y, HIRATA M, HASUWA H et al:A metalloprotease-disintegrin, MDC9/ meltrin-y/ADAM9 and PKC-8 are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J. (1998) 17:7260–7272.
   PubMed Web of Science ®Google Scholar
• HINKLE CL, SUNNARBORG SW, LOISELLE D et al: Selective roles for tumor necrosis factor-a-converting enzyme/ ADAM17 in the shedding of the epidermal growth factor receptor ligand family: the juxtamembrane stalk determines cleavage efficiency. J. Biol. Chem. (2004) 279:24179–24188.
   PubMed Web of Science ®Google Scholar
• YAN Y, SHIRAKABE K, WERB Z: The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G-protein-coupled receptors. J. Cell Biol. (2002) 158:221–226.
   PubMed Web of Science ®Google Scholar
• TANIDA S, JOH T, ITOH K et al: The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells. Gastroenterology (2004) 127:559–569.
   PubMedGoogle Scholar
• KURISAKI T, MASUDA A, SUDO K et al: Phenotypic analysis of meltrin a (ADAM12)-deficient mice: involvement of meltrin a in adipogenesis and myogenesis. MoL Cell Biol. (2003) 23:55–61.
   PubMed Web of Science ®Google Scholar
• ASAKURA M, KITAKAZE M, TAKASHIMA Set al: Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. (2002) 8:35–40.
   PubMed Web of Science ®Google Scholar
• SUNNARBORG SW, HINKLE CL, STEVENSON M et al: Tumor necrosis factor-a converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J. Biol Chem. (2002) 277:12838–12845.
   PubMed Web of Science ®Google Scholar
• SAHIN U, WESKAMP G, KELLY K et al: Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol. (2004) 164:769–779.
   PubMed Web of Science ®Google Scholar
• PESCHON JJ, SLACK JL, REDDY P et al.: An essential role for ectodomain shedding in mammalian development. Science (1998) 282:1281–1284.
   PubMed Web of Science ®Google Scholar
• JACKSON LF, QIU TH, SUNNARBORG SW et al.: Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J. (2003) 22:2704–2716.
   PubMed Web of Science ®Google Scholar
• MANN GB, FOWLER KJ, GABRIEL A et al.: Mice with a null mutation of the TGF-a gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell (1993) 73:249–261.
   PubMed Web of Science ®Google Scholar
• MERLOS-SUAREZ A. RUIZ-PAZ S, BASELGA J, ARRIBAS J: Metalloprotease-dependent protransforming growth factor-a ectodomain shedding in the absence of tumor necrosis factor-a-converting enzyme. 1 Biol. Chem. (2001) 276:48510–48517.
   Google Scholar
• SUZUKI M, RAAB G, MOSES MA et al.: Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. 1 Biol. Chem. (1997) 272:31730–31737.
   Google Scholar
• YU WH, WOESSNER JF JR, MCNEISH JD, STAMENKOVIC I: CD44 anchors the assembly of matrilysin/ MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev. (2002) 16:307–323.
   PubMed Web of Science ®Google Scholar
• HAO L, DU M, LOPEZ-CAMPISTROUS A. FERNANDEZ-PATRON C: Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ. Res. (2004) 94:68–76.
   Google Scholar
• RIO C, BUXBAUM JD, PESCHON JJ, CORFAS G: Tumor necrosis factor-a-converting enzyme is required for cleavage of erbB4/HER4. 1 Biol. Chem. (2000) 275:10379–10387.
   PubMed Web of Science ®Google Scholar
• NI CY, MURPHY MP, GOLDE TE, CARPENTER G: y-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (2001) 294:2179–2181.
   PubMed Web of Science ®Google Scholar
• CHENG QC, TIKHOMIROV 0, ZHOU W CARPENTER G: Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment. J. Biol. Chem. (2003) 278:38421–38427.
   PubMedGoogle Scholar
• LEE H, AKITA RW, SLIWKOWSKI MX, MAIHLE NJ: A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. Cancer Res. (2001) 61:4467–4473.
   PubMedGoogle Scholar
• KRIEGLER M, PEREZ C, DEFAY K et al.: A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell (1988) 53:45–53.
   PubMed Web of Science ®Google Scholar
• GEARING AJ, BECKETT P, CHRISTODOULOU M et al.: Processing of tumour necrosis factor-a precursor by metalloproteinases. Nature (1994) 370:555–557.
   PubMed Web of Science ®Google Scholar
• MCGEEHAN GM, BECHERER JD, BAST RC JR. et al.: Regulation of tumour necrosis factor-a processing by a metalloproteinase inhibitor. Nature (1994) 370:558–561.
   Google Scholar
• MOSS ML, JIN SL, MILLA ME et al.: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-a. Nature (1997) 385:733–736.
   PubMed Web of Science ®Google Scholar
• BLACK RA, RAUCH CT, KOZLOSKY CJ et al.: A metalloproteinase disintegrin that releases tumour-necrosis factor-a from cells. Nature (1997) 385:729–733.
   PubMed Web of Science ®Google Scholar
• ZHENG Y, SAFTIG P, HARTMANN D, BLOBEL C: Evaluation of the contribution of different ADAMs to tumor necrosis factor-a (TNF-a) shedding and of the function of the TNF-a ectodomain in ensuring selective stimulated shedding by the TNF-a convertase (TACE/ADAM17). J. Biol. Chem. (2004) 279:42898–42906.
   PubMed Web of Science ®Google Scholar
• ENGLISH WR, PUENTE XS, FREIJE JM et al.: Membrane Type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-a convertase activity but does not activate pro-MMP2. J. Biol. Chem. (2000) 275:14046–14055.
   PubMed Web of Science ®Google Scholar
• AMOUR A. KNIGHT CG, ENGLISH WRet al.: The enzymatic activity of ADAIVI8 and ADAM9 is not regulated by TIMPs. FEBS Lett. (2002) 524:154–158.
   Google Scholar
• HARO H, CRAWFORD HC, FINGLETON B et al.: Matrix metalloproteinase-7-dependent release of tumor necrosis factor-a in a model of herniated disc resorption. J. Clin. Invest. (2000) 105:143–150.
   PubMed Web of Science ®Google Scholar
• MOHAN MJ, SEATON T, MITCHELL J et al.: The tumor necrosis factor-a converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry (2002) 41:9462–9469.
   PubMed Web of Science ®Google Scholar
• XANTHOULEA S, PASPARAKIS M, KOUSTENI S et al.: Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J. Exp. Med. (2004) 200:367–376.
   PubMed Web of Science ®Google Scholar
• PAN Y, LLOYD C, ZHOU H et al.: Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature (1997) 387:611–617.
   PubMed Web of Science ®Google Scholar
• BAZAN JF, BACON KB, HARDIMAN G et aL: A new class of membrane-bound chemokine with a CX3C motif. Nature (1997) 385:640–644.
   PubMed Web of Science ®Google Scholar
• SUGAYA M, NAKAMURA K, MITSUI H et al.: Human keratinocytes express fractalkine/CX3CL1. 1 DermatoL Sci. (2003) 31:179–187.
   Google Scholar
• HUNDHAUSEN C, MISZTELA D, BERKHOUT TA et al.: The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood (2003) 102:1186–1195.
   PubMed Web of Science ®Google Scholar
• GARTON KJ, GOUGH PJ, BLOBEL CP et al.: Tumor necrosis factor-a-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). 1 Biol. Chem. (2001) 276:37993–38001.
   Google Scholar
• GOUGH PJ, GARTON KJ, WILLE PT et aL: A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16.1 Immunol. (2004) 172:3678–3685.
   PubMed Web of Science ®Google Scholar
• ABEL S, HUNDHAUSEN C, MENTLEIN R et aL: The transmembrane CXC-chemokine ligand 16 is induced by IFN-y and TNF-a and shed by the activity of the disintegrin-like metalloproteinase ADAM10. 1 ImmunoL (2004) 172:6362–6372.
   PubMed Web of Science ®Google Scholar
• MATTHEWS V, SCHUSTER B, SCHUTZE S et aL: Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). 1 Biol. Chem. (2003) 278:38829–38839.
   PubMed Web of Science ®Google Scholar
• GROSSMAN RM, KRUEGER J, YOURISH D et aL: Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl. Acad. ScLUSA (1989) 86:6367–6371.
   PubMed Web of Science ®Google Scholar
• INAOKI M, SATO S, SHIMADA Y et al.: Decreased expression levels of L-selectin on subsets of leucocytes and increased serum L-selectin in severe psoriasis. Clin. Exp. Immunol (2000) 122:484–492.
   PubMed Web of Science ®Google Scholar
• TU L, POE JC, KADONO T et al.: A functional role for circulating mouse L-selectin in regulating leukocyte/ endothelial cell interactions in vivo. J. Immunol. (2002) 169:2034–2043.
   PubMedGoogle Scholar
• GARTON KJ, GOUGH PJ, PHILALAY J et al.: Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-a-converting enzyme (ADAM17). J. Biol Chem. (2003) 278:37459–37464.
   PubMed Web of Science ®Google Scholar
• MCQUIBBAN GA, GONG JH, TAM EM et al.: Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science (2000) 289:1202–1206.
   PubMed Web of Science ®Google Scholar
• MCQUIBBAN GA, GONG JH, WONG JP et al.: Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood (2002) 100:1160–1167.
   PubMed Web of Science ®Google Scholar
• ITO A, MUKAIYAMA A, ITOH Y et ell.:Degradation of interleukin 10 by matrix metalloproteinases. J. Biol Chem. (1996) 271:14657–14660.
   Google Scholar
• VAN DEN STEEN PE, PROOST P, WUYTS A et al.: Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-a and leaves RANTES and MCP-2 intact. Blood (2000) 96:2673–2681.
   Google Scholar
• GOISHI K, HIGASHIYAMA S, KLAGSBRUN M et al.: Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. Mol. Biol. Cell. (1995) 6:967–980.
   PubMedGoogle Scholar
• HIGASHIYAMA S, IWAMOTO R, GOISHI K et al.: The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J. Cell Biol (1995) 128:929–938.
   PubMed Web of Science ®Google Scholar
• INUI S, HIGASHIYAMA S, HASHIMOTO K et al.: Possible role of coexpression of CD9 with membrane-anchored heparin-binding EGF-like growth factor and amphiregulin in cultured human keratinocyte growth. J. Cell Physiol. (1997) 171:291–298.
   PubMedGoogle Scholar
• SHI W, FAN H, SHUM L, DERYNCK R: The tetraspanin CD9 associates with transmembrane TGF-a and regulates TGF-a-induced EGF receptor activation and cell proliferation. J. Cell Biol. (2000) 148:591–602.
   PubMed Web of Science ®Google Scholar
• IWAMOTO R, MEKADA E: Heparin-binding EGF-like growth factor: a juxtacrine growth factor. Cytokine Growth Factor Rev. (2000) 11:335–344.
   PubMed Web of Science ®Google Scholar
• TOKUMARU S, HIGASHIYAMA S, ENDO T et al.: Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing. J. Cell Biol (2000) 151:209–220.
   PubMed Web of Science ®Google Scholar
• •Ectodomain shedding of EGFR ligands is required for keratinocyte migration.
   Google Scholar
• PIEPKORN M, PITTELKOW MR, COOK PW: Autocrine regulation of keratinocytes: the emerging role of heparin-binding, epidermal growth factor-related growth factors. J. Invest. Dermatol (1998) 111:715–721.
   PubMed Web of Science ®Google Scholar
• •Interaction of keratinocytes and leukocytes through shedding of HB-EGF is postulated.
   Google Scholar
• YAMAZAKI S, IWAMOTO R, SAEKI K et al.: Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalities. J. Cell Biol. (2003) 163:469–475.
   PubMed Web of Science ®Google Scholar
• IWAMOTO R, YAMAZAKI S, ASAKURA M et al.: Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc. Natl Acad. Sci. USA (2003) 100:3221–3226.
   PubMed Web of Science ®Google Scholar
• KANSRA S, STOLL SW, JOHNSON JL, ELDER JT: Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK. Md. Biol. Cell. (2004) 15:4299–4309.
   PubMedGoogle Scholar
• STOLL SW, KANSRA S, PESHICK S et al.: Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes. Neop/asia (2001) 3:339–350.
   PubMedGoogle Scholar
• RIESE DJ 2ND, KOMURASAKI T, PLOWMAN GD, STERN DF: Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2. j Biol Chem. (1998) 273:11288–11294.
   PubMed Web of Science ®Google Scholar
• ELENIUS K, PAUL S, ALLISON G et al.: Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J. (1997) 16:1268–1278.
   PubMedGoogle Scholar
• ZEIGLER ME, CHI Y, SCHMIDT T, VARANI J: Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J. Cell Physiol (1999) 180:271–284.
   PubMed Web of Science ®Google Scholar
• SHI CS, KEHRL JH: Pyk2 amplifies epidermal growth factor and c-Src-induced Stat3 activation. J. Biol Chem. (2004) 279:17224–17231.
   PubMed Web of Science ®Google Scholar
• SANO S, Cl-JAN KS, CARBAJAL S et al.: Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. (2005) 11:43–49.
   PubMedGoogle Scholar
• •Overexpression of Stat3 causes psoriasis-like skin phenotypes in mice.
   Google Scholar
• MASCIA F, MARIANI V, GIROLOMONI G, PASTORE S: Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am. Pathol (2003) 163:303–312.
   PubMed Web of Science ®Google Scholar
• MATTEI M, CARNIERI E, POLITI V et al.: Inhibition of contact hypersensitivity reaction to picryl chloride: effect of small molecular weight peptidomimetic compounds possessing inhibitory activity against metalloproteinases. Int. Immunopharmacol (2002) 2:699–710.
   PubMedGoogle Scholar
• ALBANELL J, ROJO F, AVERBUCH S et al.: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol (2002) 20:110–124.
   PubMed Web of Science ®Google Scholar
• •Decreased turnover rate of epidermis in patients treated with an EGFR tyrosine kinase inhibitor is described.
   Google Scholar
• NANBA D, HIGASHIYAMA S: Dual intracellular signaling by proteolytic cleavage of membrane-anchored heparin-binding EGF-like growth factor. Cytokine Growth Factor Rev. (2004) 15:13–19.
   PubMedGoogle Scholar
• NANBA D, MAMMOTO A. HASHIMOTO K, HIGASHIYAMA S: Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZE J. Cell Biol. (2003) 163:489–502.
   PubMedGoogle Scholar
• •Novel physiological roles of carboxy terminal region of HB-EGF are discussed.
   Google Scholar
• LOCKSLEY RM, KILLEEN N, LENARDO MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell (2001) 104:487–501.
   PubMed Web of Science ®Google Scholar
• WAJANT H, PFIZENMAIER K, SCHEURICH P: Tumor necrosis factor signaling. Cell Death Differ. (2003) 10:45–65.
   PubMed Web of Science ®Google Scholar
• LEE TH, HUANG Q, OIKEMUS S et al.: The death domain kinase RIP1 is essential for tumor necrosis factor-a signaling to p38 mitogen-activated protein kinase. MoL Cell Biol. (2003) 23:8377–8385.
   PubMedGoogle Scholar
• BEYAERT R, CUENDA A, VANDEN BERGHE Wet al.: The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J. (1996) 15:1914–1923.
   Google Scholar
• ECHIGO T, HASEGAWA M, SHIMADAY et al.: Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation. J. Allergy Clin. ImmunoL (2004) 113:940–948.
   PubMedGoogle Scholar
• CAMBIEN B, POMERANZ M, SCHMID-ANTOMARCHI H et aL: Signal transduction pathways involved in soluble fractalkine-induced monocytic cell adhesion. Blood (2001) 97:2031–2037.
   PubMedGoogle Scholar
• MATLOUBIAN M, DAVID A, ENGEL S et al.: A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat. ImmunoL (2000) 1:298–304.
   PubMed Web of Science ®Google Scholar
• CHANDRASEKAR B, BYSANI S, MUMMIDI S: CXCL16 signals via Go phosphatidylinositol 3-kinase, Akt, IKB kinase, and nuclear factor-KB and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J. Biol. Chem. (2004) 279:3188–3196.
   PubMed Web of Science ®Google Scholar
• HOLVOET S, VINCENT C, SCHMITT D, SERRES M: The inhibition of MAPK pathway is correlated with down-regulation of MMP-9 secretion induced by TNF-a in human keratinocytes. Exp. Cell Res. (2003) 290:108–119.
   PubMed Web of Science ®Google Scholar
• SCOTT KA, ARNOTT CH, ROBINSON SC et aL: TNF-a regulates epithelial expression of MMP-9 and integrin aJ36 during tumour promotion. A role for TNF-a in keratinocyte migration? Oncogene (2004) 23:6954–6966.
   PubMed Web of Science ®Google Scholar
• HOBBS R1\4, SILVA-VARGAS V GROVES R, WATT FM: Expression of activated MEK1 in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions. J. Invest. DermatoL (2004) 123:503–515.
   PubMedGoogle Scholar
• VARANI J, KANG S, STOLL S, ELDER JT: Human psoriatic skin in organ culture: comparison with normal skin exposed to exogenous growth factors and effects of an antibody to the EGF receptor. Pathobiology (1998) 66:253–259.
   PubMed Web of Science ®Google Scholar
• GILLITZER R, BERGER R, MIELKE V et al.: Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ. J. Invest. DermatoL (1991) 97:73–79.
   PubMed Web of Science ®Google Scholar
• VALYI-NAGY I, JENSEN PJ, ALBELDA SM, RODECK U: Cytokine-induced expression of transforming growth factor-a and the epidermal growth factor receptor in neonatal skin explants. J. Invest. DermatoL (1992) 99:350–356.
   PubMed Web of Science ®Google Scholar
• TAKENOBU H, YAMAZAKI A, HIRATA M et aL: The stress- and the inflammatory cytokine-induced ectodomain shedding of heparin-binding EGF-like growth factor is mediated by p38 MAPK, distinct from TPA-induced and LPA-induced signaling cascades. J. BioL Chem. (2003).
   Google Scholar
• HOBBS RM, WATT FM: Regulation of interleukin-la expression by integrins and epidermal growth factor receptor in keratinocytes from a mouse model of inflammatory skin disease. J. Biol. Chem. (2003) 278:19798–19807.
   PubMedGoogle Scholar
• PRENZEL N, ZWICK E, DAUB H et aL: EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature (1999) 402:884–888.
   PubMed Web of Science ®Google Scholar
• •Transactivation of EGFR by GPCR through ectodomain shedding of HB-EGF is described.
   Google Scholar
• MARQUES SA, DY LC, SOUTHALL MD et al.: The platelet-activating factor receptor activates the extracellular signal-regulated kinase mitogen-activated protein kinase and induces proliferation of epidermal cells through an epidermal growth factor-receptor-dependent pathway. J. PharmacoL Exp. Ther. (2002) 300:1026–1035.
   PubMed Web of Science ®Google Scholar
• DUAN JJ, CHEN L, WASSERMAN ZR et aL: Discovery of y-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor-a-converting enzyme: design, synthesis, and structure-activity relationships. J. Med. Chem. (2002) 45:4954–4957.
   PubMed Web of Science ®Google Scholar
• XUE CB, HEX, RODERICK J et al.: Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-a converting enzyme inhibitors. Part 1: lead identification. Bioorg. Med. Chem. Lett. (2003) 13:4293–4297.
   Google Scholar
• CHERNEY RJ, DUAN JJ, VOSS ME et aL: Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-a converting enzyme inhibitors. J. Med. Chem. (2003) 46:1811–1823.
   PubMed Web of Science ®Google Scholar
• LEVIN JI, NELSON FC, DELOS SANTOS E et aL: Benzodiazepine inhibitors of the MMPs and TACE. Part 2. Bioorg. Med. Chem. Lett. (2004) 14:4147–4151.
   PubMedGoogle Scholar
• DUAN JJ, LU Z, XUE CB et aL: Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyfiacetamides as potent and selective inhibitors of tumor necrosis factor-a converting enzyme (TACE). Bioorg. Med. Chem. Lett. (2003) 13:2035–2040.
   PubMedGoogle Scholar
• XUE CB, HEX, RODERICK Jet al.: Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-a converting enzyme inhibitors. Part 2: lead optimization. Bioorg. Med. Chem. Lett. (2003) 13:4299–4304.
   Google Scholar
• XUE CB, CHEN XT, HEX et aL: Synthesis and structure-activity relationship of a novel sulfone series of TNF-a converting enzyme inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:4453–4459.
   PubMed Web of Science ®Google Scholar
• KAMEI N, TANAKA T, KAWAI K et al.: Reverse hydroxamate-based selective TACE inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:2897–2900.
   PubMed Web of Science ®Google Scholar
• SAWA M, KIYOI T, KUROKAWA K et al.: New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids. J. Med. Chem. (2002) 45:919–929.
   PubMed Web of Science ®Google Scholar
• MORIYAMA H, TSUKIDA T, INOUE Y et aL: Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents. J. Med. Chem. (2004) 47:1930–1938.
   PubMed Web of Science ®Google Scholar
• •MMP/ADAM inhibitors as anti-psoriatic drug for topical use are described. Topical application of a MMP/ADAM inhibitor suppressed PMA-induced epidermal hyperplasia in mice.
   Google Scholar
• TSUKIDA T, MORIYAMA H, INOUE Y et aL: Synthesis and biological activity of selective azasugar-based TACE inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:1569–1572.
   PubMedGoogle Scholar
• TRIFILIEFF A, WALKER C, KELLER T et al.: Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-a converting enzyme and matrix metalloproteinases, in models of airway inflammation. Br. J. PharmacoL (2002) 135:1655–1664.
   PubMed Web of Science ®Google Scholar
• KOTTIRSCH G, KOCH G, FEIFEL R, NEUMANN U: B-Aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor-a converting enzyme. J. Med. Chem. (2002) 45:2289–2293.
   PubMedGoogle Scholar
• LETAVIC MA, AXT MZ, BARBERIA JT et al.: Synthesis and biological activity of selective pipecolic acid-based TNF-a converting enzyme (TACE) inhibitors. Bioorg-. Med. Chem. Lett. (2002) 12:1387–1390.
   PubMed Web of Science ®Google Scholar
• LETAVIC MA, BARBERIA JT, CARTY TJ et al.: Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-a converting enzyme inhibitors. Bioorg-. Med. Chem. Lett. (2003) 13:3243–3246.
   PubMed Web of Science ®Google Scholar
• BECK G, BOTTOMLEY G, BRADSHAW D et al.: (L)-2(R)-[1(S)-(Hy cfroxy carbamoy1)-4-pheny1-3-buteny1]-2' -isobuty1-2' -(meth anesulfony1)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-a convertase. j PharmacoL Exp. Ther. (2002) 302:390–396.
   PubMed Web of Science ®Google Scholar
• LEVIN JI, CHEN JM, DU MT et al.: Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAP. of the acetylenic P1' group. Bioorg-. Med. Chem. Lett. (2002) 12:1199–1202.
   Google Scholar
• LEVIN JI, CHEN JM, CHEUNG K et al.: Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates. Bioorg-. Med. Chem. Lett. (2003) 13:2799–2803.
   Google Scholar
• ZASK A, GUY, ALBRIGHT JD et aL: Synthesis and SAP. of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors. Bioorg-. Med. Chem. Lett. (2003) 13:1487–1490.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, XU J, LEVIN J et al.: Identification and characterization of 4-114-(2-butynyloxy)phenyllsulfonyll -N-hydroxy-2,2-dimethyl-(3S)thiomorpho linecarboxamide (TMI-1), a novel dual tumor necrosis factor-a-converting enzyme/ matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J. PharmacoL Exp. Ther. (2004) 309:348–355.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, HEGEN M, XU J et al.: Characterization of (2R,3S)-2-(114-(2-butynyloxy)phenyllsulfonyllamino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-a converting enzyme. Int. Immunopharmacol. (2004) 4:1845–1857.
   PubMed Web of Science ®Google Scholar
• OHM, IM I, LEE YJ et al.: Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors. Bioorg-. Med. Chem. Lett. (2004) 14:6071–6074.
   PubMedGoogle Scholar
• GROBELNY D, PONCZ L, GALARDY RE: Inhibition of human skin fibroblast collagenase, thermolysin, and Pseuclomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry (1992) 31:7152–7154.
   PubMed Web of Science ®Google Scholar
• STEWARD WP, THOMAS AL: Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Expert Opin. Investig-. Drugs (2000) 9:2913–2922.
   PubMed Web of Science ®Google Scholar
• WALL L, TALBOT DC, BRADBURY P, JODRELL DI: A Phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. Br. J. Cancer. (2004) 90:800–804.
   PubMed Web of Science ®Google Scholar
• HANDE KR, COLLIER M, PARADISO L et al.: Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clin. Cancer Res. (2004) 10:909–915.
   PubMed Web of Science ®Google Scholar
• PLANTING k VAN DER GAAST A, SCHOFFSKI P et al.: A Phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors. Cancer Chemother. PharmacoL (2004).
   Google Scholar
• RIZVI NA, HUMPHREY JS, NESS EA et al.: A Phase I study of oral BMS-275291, a novel nonhydroxamate shedclase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin. Cancer Res. (2004) 10:1963–1970.
   PubMed Web of Science ®Google Scholar
• HEATH El, O'REILLY S, HUMPHREY R et al.: Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother. PharmacoL (2001) 48:269–274.
   Google Scholar
• LEVITT NC, ESKENS FA, O'BYRNE KJ et al.: Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CG527023A), in patients with advanced solid cancer. Clin. Cancer Res. (2001) 7:1912–1922.
   Google Scholar